Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma

Fig. 3

MAP17 expression predicts platin sensitivity in lung adenocarcinoma. a Correlation of cisplatin (up) and carboplatin (down) sensitivity in lung adenocarcinoma cell lines based on MAP17 expression. b Correlation of cisplatin sensitivity in adenocarcinoma cell lines based on MAP17 expression, with data obtained from the GDSC database. c Cisplatin (up) and carboplatin (down) sensitivity in MAP17-overexpressing and MAP17-silenced lung adenocarcinoma cell lines. d Determination of MAP17 mRNA expression in lung adenocarcinoma PDXs. e Tumour growth assessment of carboplatin-treated adenocarcinoma PDXs with differential MAP17 expression. f Kaplan-Meier overall survival curves for lung adenocarcinoma patients from the TCGA database (Additional file 1: Table S6) treated with cisplatin, carboplatin, or both. Patients were divided based on MAP17 expression levels into two groups, below or above the 75th percentile of expression

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us